INFORMATION DISCLOSURE

PCT

I hereby certify that the correspondence is being deposited with the United States ostal Service as first class mail in an envelope addressed to:

**Assistant Commissioner for Patents** 

Washington, D.C. 20231 on May

28

2002

STATEMENT Patent Application Docket No. GJE-83

Serial No. 10/019,906

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Peter Richardson, Peter Cox

Serial No.

10/019,906

Conf. No.

7158

Filed

December 31, 2001

For

A Method for Amplifying Low Abundance Nucleic Acid Sequences and

Means for Performing Said Method

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. In accordance with 37 CFR §1.56, the Applicants hereby request that the references cited in the international search report and listed on the attached form PTO-1449 be made of record and considered in the examination of the subject application. The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

2421 N.W. 41st Street, Suite A-1

Gainesville, Florida 32606-6669

DRS/la

Attachment:

Form PTO-1449; and copies of references cited therein

Im

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/019,906 INFORMATION DISCLOSURE **Filing Date** December 31, 2001 STATEMENT BY APPLICANT First Named Inventor Peter Richardson (use as many sheets as necessary) **Art Unit Examiner Name** of 2 **Attorney Docket Number** GJE-83 Sheet 1

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	U1	US-6,066,457	05-23-2000	Hampson et al.		
	U2	US-				
	U3	US-				
	U4	US-				
	U5	US-				
	U6	US-				
	U7	US-				
	U8	US-				
	U9	US-				
	U10	US-				
	U11	US			<u> </u>	
	U12	US-				
	U13_	US-				
	U14	US-				
	U15	US-	<u> </u>			
	U16	US-				
	U17	US-	<del></del>			
	U18	US-	<del></del>			
	U19	US-	<del>                                      </del>			
	U20	US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	F1	WO 91/15601 A1	10-17-1991	Shuldiner et al.		<u> </u>
	F2	WO 98/08973 A1	03-05-1998	Hampson et al.		
	F3	WO 00/08208 A2	02-17-2000	Freeman et al.		
	F4					<u> </u>
	F5					
	F6					ļ. —
	F7					-
	F8					┡
	F9					
	F10		1			1

Examiner	Date
Signature	Considered
L Oidirataio	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, the paper to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number 10/019,906

Filing Date December 31, 2000

First Named Inventor Peter Richardson

Group Art Unit

Examiner Name

Attorney Docket Number GJE-83

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	R1	CHEUNG, VIVIAN G. and STANLEY F. NELSON (December 1996) "Whole genome amplification using a degenerate oligonucleotide primer allows hundreds of genotypes to be performed on less than one nanogram of genomic DNA" <i>Proc. Natl. Acad. Sci.</i> USA 93:14676-14679.			
_	R2	DIXSON, ALISTAIR K. et al. (1998) "Expression profiling of single cells using 3 prime end amplification (TPEA) PCR" Nucleic Acids Research 26(19):4427-4431.			
	R3	EBERWINE, JAMES et al. (April 1992) "Analysis of gene expression in single live neurons" Proc. Natl. Acad. Sci. USA 89:3010-3014.			
	R4	FROUSSARD, PATRICK (1992) "A random-PCR method (rPCR) to construct whole cDNA library from low amounts of RNA" <i>Nucleic Acids Research</i> 20(11):2900			
	R5	RICHARDSON et al. (August 1998) "Relating Gene Expression to Cell Function Using A Novel Single Cell PCR Method" European Journal of Neuroscience 10(10):10307, abstract only.			
	R6	TELENIUS, HAKAN et al. (1992) "Degenerate Oligonucleotide-Primed PCR: General Amplification of Target DNA by a Single Degenerate Primer" <i>Genomics</i> 13:718-725.			
	R7	ZHAO, S. et al. (May 1998) "3'-End cDNA Pool Suitable for Differential Display from a Small Number of Cells" BioTechniques 24:842-852.			
	R8	ZHAO, SHANCHUAN, SIEW LOON OOI and ARTHUR B. PARDEE (1995) "Short Technical Reports: New Primer Strategy Improves Precision of Differential Display" biotechniques 18(5):842-850.			
	R9				
	R10				
	R11				
	R12				
	R13				

Examiner	Date
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.